2 completed, 2 terminated, 1 unknown. 4 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Donepezil placebo: new trials by email Literature Review of Donepezil placebo trials Research Report on Donepezil placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease | Phase 2 / Phase 3 | Unknown | Mediforum Ltd., Co. | 312 | 2020-11-27 | 2023-04-18 |
| Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers BPN14770, BPN14770 placebo, Donepezil - Alzheimer Disease | Phase 1 | Completed | Tetra Discovery Partners | 38 | 2017-01-01 | 2018-10-16 |
| TAK-071 Scopolamine-Induced Cognitive Impairment Study Scopolamine, TAK-071, Donepezil - Healthy Volunteers | Phase 1 | Terminated | Takeda | 18 | 2016-11-21 | 2019-06-14 |
| Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants TAK-071, Donepezil, TAK-071 Placebo - Alzheimer Disease, Healthy Volunteers | Phase 1 | Terminated | Takeda | 179 | 2016-05-05 | 2019-06-10 |
| Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults Roflumilast, Roflumilast placebo, Donepezil - Memory Impairment, Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 27 | 2014-01-01 | 2017-02-01 |
Alzheimer Disease (4) · Dementia (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Memory Disorders (1) · Nervous System Diseases (1)
Takeda (2) · AstraZeneca (1) · Mediforum Ltd., Co. (1) · Tetra Discovery Partners (1)
United States (3) · South Korea (1) · United Kingdom (1)